

Consultants Report: Q2 2024

SJVIA- EmpiRx Health – Q1 2024 Highlights


- SJVIA's total plan cost increased in Q2 2024 by 11% to \$7,763,537
 - Tulare: \$3,309,035 in Plan Cost
 - Fresno: \$4,454,502 in Plan Cost
 - o The increase in plan spend can be attributed to an increase in Total Rx count.
- Specialty claims plan cost increased in Q2 2024
 - O Q2 2024 \$2,898,804 (Q1 2024 \$2,608,106)
 - Tulare: \$1,296,197
 - Fresno: \$1,581,500
 - o 729 Scripts filled in Q2 2024 (Q1 2024 685)
 - Tulare: 263Fresno: 466
- Patient Saver Plus Program Savings (Pending Data from EmpiRx)

(formerly known as Variable Copay Assistance (VCAP) aka bWell)

- SJVIA Total Savings \$(Pending Data from EmpiRx)
 - Tulare: \$(Pending Data from EmpiRx)
 - Fresno: \$(Pending Data from EmpiRx)
- Rebates:
 - Q1-2024 net rebate amount is \$1,618,600 (includes \$382,745 true up payment in August)
 - o Q2 -2024 net rebate amount is \$1,730,100
- Clinical Savings: January June 2024: \$1,100,000
 - SJVIA Tulare: Jan-Jun 2024, \$(Pending Data from EmpiRx)
 - SJVIA Fresno: Jan-Jun 2024, \$(Pending Data from EmpiRx)

KPS Audit


KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees.



Top Clinical Cost Drivers by Drug

					6 months	6 months	6 months	12 months	12 months	12 months
2023 Rank	2024 Rank	Drug Label Name	Drug Group	Speciality Indicator	2024 Claim Count	2024 Utilizers	2024 Ingredient Cost	2023 Claim Count	2023 Utilizers	2023 Ingredient Cost
1	1	OZEMPIC	ANTIDIABETICS	N	1,060	327	\$1,446,931.02	1,512	324	\$1,926,539.77
3	2	WEGOVY	ADHD/ANTI-NARCOLEPSY/ANTI-	N	645	218	\$994,030.61	747	235	\$1,080,538.77
11	3	MOUNJARO	ANTIDIABETICS	N	476	145	\$600,034.95	388	105	\$447,920.71
2	4	HUMIRA PEN	ANALGESICS - ANTI-INFLAMMATORY	Υ	72	22	\$576,266.67	164	23	\$1,396,123.48
4	5	DUPIXENT	DERMATOLOGICALS	Υ	130	34	\$486,489.18	256	36	\$915,953.26
6	6	JARDIANCE	ANTIDIABETICS	N	291	145	\$403,921.72	455	146	\$590,996.57
9	7	TREMFYA	DERMATOLOGICALS	Υ	22	9	\$283,560.11	36	10	\$452,800.84
23	8	SKYRIZI PEN	DERMATOLOGICALS	Υ	12	7	\$243,633.23	13	5	\$251,734.67
7	9	EMPAVELI	HEMATOLOGICAL AGENTS - MISC.	Υ	6	1	\$235,261.62	13	1	\$492,496.16
8	10	FARXIGA	ANTIDIABETICS	N	160	86	\$232,279.00	368	108	\$472,250.37
12	11	STELARA	DERMATOLOGICALS	Υ	8	3	\$216,506.00	19	6	\$429,345.78
n/a	12	KORLYM	ANTIDIABETICS	Υ	5	1	\$206,530.56	0	0	\$0.00
5	13	TRULICITY	ANTIDIABETICS	N	154	73	\$204,837.74	582	128	\$830,325.09
10	14	RYBELSUS	ANTIDIABETICS	N	111	54	\$200,343.48	282	75	\$451,446.42
13	15	RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	Υ	30	7	\$189,698.59	63	10	\$416,168.01
16	16	JANUVIA	ANTIDIABETICS	N	140	67	\$175,684.02	269	86	\$325,927.29
21	17	BIKTARVY	ANTIVIRALS	Υ	45	11	\$174,061.72	71	10	\$258,877.73
14	18	LYNPARZA	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Υ	10	2	\$170,835.10	21	3	\$341,441.58
19	19	SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Υ	11	2	\$163,541.58	16	2	\$273,417.94
15	20	ELIQUIS	ANTICOAGULANTS	N	148	65	\$159,076.03	347	88	\$330,826.02
n/a	21	VUMERITY	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS -	Υ	17	3	\$153,224.57	0	0	\$0.00
n/a	22	TRIKAFTA	RESPIRATORY AGENTS - MISC.	Υ	5	1	\$138,570.10	0	0	\$0.00
17	23	ENBREL SURECLICK	ANALGESICS - ANTI-INFLAMMATORY	Υ	20	6	\$138,206.96	44	9	\$305,546.68
22	24	ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Υ	6	1	\$130,485.36	12	1	\$252,138.48
n/a	25	LENVIMA 20 MG DAILY DOSE	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Υ	5	1	\$126,611.10	0	0	\$0.00

Items in White had no change in rank Orange went up in rank compared to 2023 Green went down in rank Blue are new medications



New Medications Available in the Market

Update on Humira Biosimilar

- EmpiRx added the below Humira biosimilar's as preferred products to the formulary alongside Humira in 2023
 - Hadlima (adalimumab-bwwd)
 - Unbranded-Hulio (adalimumab-fkjp)
 - As of 1/1/2025 Humira is moving to a 2nd line treatment under Step Therapy.
 - The biosimilars will be 1st line.
 - Existing utilizers will be left on Humira for the duration of the existing PA.
 - New utilizers will have to try a 1st line agent starting 1/1/25.

New Stelara Biosimilar's

- As of July 2024, several biosimilars have been approved by the FDA but are not expected to be available until late February 2025, due to settlements and licensing agreements with Janssen Biotech, the manufacturer of Stelara.
 - Wezlana (ustekinumab-auub) was FDA approved on Oct. 31, 2023, as an interchangeable biosimilar to Stelara.
 It is made by the pharmaceutical company Amgen, Inc.
 - Pricing TBD
 - In April of 2024, the FDA approved <u>Selarsdi</u> (ustekinumab-aekn), a Stelara biosimilar made by the pharmaceutical companies Alvotech and Teva Pharmaceuticals. It is not an interchangeable biosimilar.
 - Pricing TBD
 - In July of 2024, the FDA approved <u>Pyzchiva</u> (ustekinumab-ttwe) as an interchangeable biosimilar to Stelara.
 Pyzchiva is made by Samsung Bioepis.
 - Pricing TBD
- EmpiRx will be reviewing Formulary placement of the Stelara biosimilar's once they become available.

